firm news | media mention
Morris James has filed 29 cases in the Depo-Provera multidistrict litigation, adding to the growing body of claims alleging that women developed intracranial meningiomas after use of the injectable contraceptive.
The firm’s filings contend that defendants failed to warn patients and physicians in the United States about the meningioma risk associated with Depo-Provera, even though product labeling and safety communications in other countries identified meningioma-related concerns. The complaints further allege that women were not given the information needed to make informed decisions about whether to use the drug.
“These filings reflect a significant and growing body of claims by women who allege they were not adequately warned about the risk of meningioma associated with Depo-Provera,” said Keith Donovan, Managing Partner of Morris James and a leader of the firm’s Depo-Provera trial team. “As the MDL moves forward, we intend to continue pressing the facts and pursuing accountability for women were injured without the warnings they should have received.”
In one recently filed case, Morris James alleges that a Delaware woman used Depo-Provera for contraception, later developed an intracranial meningioma, and suffered significant injuries requiring medical treatment and ongoing monitoring. The complaint alleges that U.S. labeling did not warn of meningioma risk, despite labeling changes or safety communications in other jurisdictions addressing that issue.
The Depo-Provera MDL is pending in the Northern District of Florida.
Morris James continues to investigate claims involving Depo-Provera and alleged meningioma injuries.
